TN2014000412A1 - Heterocyclic compounds and their uses - Google Patents

Heterocyclic compounds and their uses

Info

Publication number
TN2014000412A1
TN2014000412A1 TNP2014000412A TN2014000412A TN2014000412A1 TN 2014000412 A1 TN2014000412 A1 TN 2014000412A1 TN P2014000412 A TNP2014000412 A TN P2014000412A TN 2014000412 A TN2014000412 A TN 2014000412A TN 2014000412 A1 TN2014000412 A1 TN 2014000412A1
Authority
TN
Tunisia
Prior art keywords
inflammatory
disorders
myelo
restricted
diseases
Prior art date
Application number
TNP2014000412A
Other languages
English (en)
Inventor
Minna Hue Thanh Bui
Timothy D Cushing
Lopez De Turiso Felix Gonzalez
Xiaolin Hao
Brian Lucas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TN2014000412A1 publication Critical patent/TN2014000412A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2014000412A 2012-04-04 2014-09-30 Heterocyclic compounds and their uses TN2014000412A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620270P 2012-04-04 2012-04-04
PCT/US2013/035203 WO2013152150A1 (fr) 2012-04-04 2013-04-04 Composés hétérocycliques et leurs utilisations

Publications (1)

Publication Number Publication Date
TN2014000412A1 true TN2014000412A1 (en) 2015-12-21

Family

ID=48142975

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000412A TN2014000412A1 (en) 2012-04-04 2014-09-30 Heterocyclic compounds and their uses

Country Status (31)

Country Link
US (2) US8716290B2 (fr)
EP (1) EP2834231B1 (fr)
JP (1) JP2015512451A (fr)
KR (1) KR20140139547A (fr)
CN (1) CN104395305A (fr)
AP (1) AP3611A (fr)
AU (1) AU2013243506A1 (fr)
CA (1) CA2869413A1 (fr)
CL (1) CL2014002686A1 (fr)
CO (1) CO7091181A2 (fr)
CR (1) CR20140503A (fr)
CY (1) CY1117487T1 (fr)
DK (1) DK2834231T3 (fr)
EA (1) EA201491823A1 (fr)
ES (1) ES2577109T3 (fr)
HR (1) HRP20160352T1 (fr)
HU (1) HUE028762T2 (fr)
IL (1) IL234822A0 (fr)
MA (1) MA37472A1 (fr)
ME (1) ME02473B (fr)
MX (1) MX2014011970A (fr)
PE (1) PE20142457A1 (fr)
PH (1) PH12014502246A1 (fr)
PL (1) PL2834231T3 (fr)
RS (1) RS54716B1 (fr)
SG (1) SG11201406316VA (fr)
SI (1) SI2834231T1 (fr)
SM (1) SMT201600211B (fr)
TN (1) TN2014000412A1 (fr)
WO (1) WO2013152150A1 (fr)
ZA (1) ZA201407037B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765768B2 (en) * 2010-11-17 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
DK2834231T3 (en) * 2012-04-04 2016-04-18 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
AR100289A1 (es) 2014-05-06 2016-09-21 Amgen Inc Formas de un inhibidor de pi3k
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
CA3013490C (fr) * 2016-03-05 2021-09-14 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Analogues de quinoleine en tant qu'inhibiteurs de phosphatidylinositol 3-kinase
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
DE602005015110D1 (de) * 2004-06-28 2009-08-06 Bayer Schering Pharma Ag 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
RS53151B (en) * 2007-03-23 2014-06-30 Amgen Inc. 3-SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR (PI3K)
ES2587738T3 (es) * 2007-12-21 2016-10-26 Ucb Biopharma Sprl Derivados de quinoxalina y quinolina como inhibidores de quinasa
CA2745280A1 (fr) * 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Medicaments a ciblage phosphatidylinositol-3-kinase p110 delta dans le traitement des troubles du snc
AU2010265974B2 (en) * 2009-06-25 2014-09-11 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
US8633313B2 (en) * 2009-12-18 2014-01-21 Amgen Inc. Heterocyclic compounds and their uses
CA2803624A1 (fr) * 2010-07-02 2012-01-05 Jason A. Duquette Composes heterocycliques et leur utilisation comme inhibiteurs de l'activite pi3k
DK2834231T3 (en) * 2012-04-04 2016-04-18 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES

Also Published As

Publication number Publication date
CO7091181A2 (es) 2014-10-21
EA201491823A1 (ru) 2015-01-30
HRP20160352T1 (hr) 2016-05-06
PE20142457A1 (es) 2015-02-07
CL2014002686A1 (es) 2015-05-08
CN104395305A (zh) 2015-03-04
KR20140139547A (ko) 2014-12-05
AU2013243506A1 (en) 2014-10-09
ME02473B (fr) 2017-02-20
CY1117487T1 (el) 2017-04-26
ES2577109T3 (es) 2016-07-13
WO2013152150A1 (fr) 2013-10-10
US20140206694A1 (en) 2014-07-24
EP2834231A1 (fr) 2015-02-11
CA2869413A1 (fr) 2013-10-10
RS54716B1 (en) 2016-08-31
PL2834231T3 (pl) 2016-07-29
US8835432B2 (en) 2014-09-16
SMT201600211B (it) 2016-08-31
AP3611A (en) 2016-02-29
EP2834231B1 (fr) 2016-03-30
HUE028762T2 (en) 2016-12-28
AP2014007979A0 (en) 2014-09-30
SI2834231T1 (sl) 2016-09-30
US20130267524A1 (en) 2013-10-10
PH12014502246A1 (en) 2014-12-15
CR20140503A (es) 2015-03-06
MX2014011970A (es) 2015-05-12
US8716290B2 (en) 2014-05-06
ZA201407037B (en) 2015-11-25
JP2015512451A (ja) 2015-04-27
MA37472A1 (fr) 2016-09-30
SG11201406316VA (en) 2014-11-27
IL234822A0 (en) 2014-12-31
DK2834231T3 (en) 2016-04-18

Similar Documents

Publication Publication Date Title
TN2012000449A1 (en) Heterocyclic compounds and their uses
MX2013007261A (es) Compuestos heterociclicos y sus usos.
MX2011013666A (es) Compuestos heterociclicos y sus usos.
MX2012015135A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2011013667A (es) Compuestos heterociclicos y sus usos.
MX2012015134A (es) Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
MX2009009968A (es) Compuestos heterociclicos y sus usos.
MX2011013510A (es) Compuestos heterociclicos y sus usos.
MX2009009913A (es) Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
MX2011013901A (es) Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
MX2012015143A (es) Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
PH12014502246A1 (en) Heterocyclic compounds and their uses
MX2012015147A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2009010050A (es) Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
MX2022001343A (es) Compuestos y composiciones para tratar trastornos hematologicos.
MX2016011036A (es) Compuestos de éter para el tratamiento de trastornos mediados por complemento.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2015015665A (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles novedosos.
CY1117196T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
AR090705A1 (es) Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
MX2016009624A (es) Compuestos heterobiciclicos novedosos como agonistas del opioide kappa.
CY1114775T1 (el) Παραγωγα 3-υποκατεστημενης κινολινης ή κινοξαλινης και η χρηση τους ως αναστολεων της 3-κινασης φωσφατιδυλινοσιτολης (ρι3κ)
UY34748A (es) Compuestos heterocíclicos y sus usos
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.